SI-B003 + Izalontamab Brengitecan

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

SI-B003 + Izalontamab Brengitecan
Treatment and conditionWhere it standsTrials
SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1